Targeting the BMP pathway in metastatic cancer

靶向转移性癌症中的 BMP 通路

• 批准号: 9325996
• 负责人: Philip Owens
• 金额: --
• 依托单位: VA EASTERN COLORADO HEALTH CARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9325996
• 关键词: Acute; Adaptive Immune System; Area; Bladder; Bone Diseases; Bone Morphogenetic Proteins; Breast Cancer Model; Calcitonin; Cardiovascular system; Cell Differentiation process; Cell Lineage; Cell Proliferation; Cell physiology; Characteristics; Chronic; Colon; Complex; Data; Development; Disease; Disseminated Malignant Neoplasm; Distant; Drug Delivery Systems; Flow Cytometry; General Population; Genetically Engineered Mouse; Goals; Growth; Health system; Histopathology; Human; Immune; Immune response; Immunologic Surveillance; Immunosuppression; Impairment; Implant; In Vitro; Injection of therapeutic agent; Lesion; Leukocytes; Long-Term Effects; Lung; Malignant Neoplasms; Malignant neoplasm of prostate; Mediating; Medicine; Metastatic Neoplasm to the Bone; Metastatic Prostate Cancer; Mus; Myelogenous; Myeloid Cell Suppression; Myeloid Cells; NK Cell Activation; Natural Killer Cells; Neoplasm Metastasis; Osteoblasts; Osteocalcin; Osteoclasts; Palliative Care; Pathway interactions; Patients; Pharmacology; Phenotype; Phosphotransferases; Process; Prostate; Prostatic Neoplasms; Protein Inhibition; Receptor Signaling; Research; Scientist; Services; Signaling Protein; Site; Soldier; Source; Testing; Toxicology; Transgenic Mice; Treatment outcome; Treatment-Related Cancer; Tumor Cell Invasion; Tumor Cell Migration; Tumor Expansion; Tumor Promotion; Tumorigenicity; Veterans; Work; Zoledronic Acid; adaptive immunity; base; bone; bone cell; bone sialoprotein; cancer diagnosis; cell type; effective therapy; experimental study; fight against; immune activation; immune function; improved; in vivo; inhibitor/antagonist; killings; macrophage; melanoma; mimicry; mortality; mouse model; neoplasm registry; neoplastic cell; novel; novel therapeutic intervention; outcome forecast; pre-clinical; prevent; prostate cancer cell; public health relevance; restoration; skeletal; small molecule; standard of care; targeted treatment; tumor; tumorigenic

 DESCRIPTION (provided by applicant): Cancer and subsequent metastatic disease continue to be a significant source of mortality. Treatment and outcome are largely determined by whether the cancer has disseminated or metastasized, and once the cancer is no longer locally confined, patient prognosis is poor. We have few treatment opportunities for patients once they have metastases, typically resulting in palliative care. This project aims to study the Bone Morphogenetic Protein (BMP) pathway in metastatic prostate cancers, which preliminary data indicates may be a target for therapy and could potentially revolutionize the management of metastatic disease. This proposal focuses on three key areas: 1) Skeletal metastases, which may be dependent upon BMP signaling to persist. 2) Myeloid cell suppression of anti-tumor immune responses, which may be BMP dependent. 3) Restoration of the adaptive immune system to kill tumor cells through targeting in vivo the myeloid immune suppressive cells BMP signaling. Use of small molecule BMP antagonists developed by VA scientists originally for cardiovascular medicine may hold promise as novel treatments in the fight against metastatic cancers.

 描述（由申请人提供）： 癌症和随后的转移性疾病仍然是死亡率的重要来源。治疗和结果在很大程度上取决于癌症是否已经扩散或转移，一旦癌症不再局限于局部，患者预后就很差。一旦患者发生转移，我们几乎没有治疗机会，通常会导致姑息治疗。该项目旨在研究转移性前列腺癌中的骨形态发生蛋白（BMP）通路，初步数据表明该通路可能是治疗靶点，并可能彻底改变转移性疾病的管理。该建议集中在三个关键领域：1）皮肤转移，其可能依赖于BMP信号传导持续存在。2)髓样细胞抑制抗肿瘤免疫应答，这可能是BMP依赖性的。3)通过靶向体内骨髓免疫抑制细胞BMP信号传导恢复适应性免疫系统以杀死肿瘤细胞。使用VA科学家最初为心血管药物开发的小分子BMP拮抗剂可能有望成为对抗转移性癌症的新型治疗方法。